MeritValue

Pharmagreen Biotech Inc.

PHBIdata completeness 63%5 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'depreciationAmortization'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'

i. The business — what you’d actually own
FigureFY 2018FY 2019FY 2020FY 2021FY 2022
Revenue—————
Net income−$1.07M1−$767,5372−$2.48M3−$4.53M4−$875,5054
Operating cash flow−$785,5345−$317,8326−$607,6347−$206,0818−$426,5688
Capital expenditure$251,3109$196,12710———
Free cash flow (derived)−$1.04M5−$513,9596———
Total debt——$30,02811——
Cash & equivalents—$62,68212$12,19612$25,30012$8,01613
Diluted shares293.1M364.9M388.4M326.0M218.7M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.08
your share of equity
Profit it earned you last year
−$0.04
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$0.08 of net worth that earned you −$0.04 last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
−25% shares · 5y

Share count is down 25% over 5 years — management has been buying back stock, quietly handing owners a bigger slice. Total debt has held roughly steady.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth —

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2018-09-30 · accession 0001273511-19-000126 (NetIncomeLoss)
  2. 10-K · period ending 2019-09-30 · accession 0001273511-21-000011 (NetIncomeLoss)
  3. 10-K · period ending 2020-09-30 · accession 0001477932-21-009538 (NetIncomeLoss)
  4. 10-K · period ending 2021-09-30 · accession 0001477932-23-000296 (NetIncomeLoss)
  5. 10-K · period ending 2018-09-30 · accession 0001273511-19-000126 (NetCashProvidedByUsedInOperatingActivities)
  6. 10-K · period ending 2019-09-30 · accession 0001273511-21-000011 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K · period ending 2020-09-30 · accession 0001477932-21-009538 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2021-09-30 · accession 0001477932-23-000296 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2018-09-30 · accession 0001273511-19-000126 (PaymentsToAcquirePropertyPlantAndEquipment)
  10. 10-K · period ending 2019-09-30 · accession 0001273511-21-000011 (PaymentsToAcquirePropertyPlantAndEquipment)
  11. 10-K · period ending 2020-09-30 · accession 0001273511-21-000011 (LongTermDebtNoncurrent)
  12. 10-K · period ending 2019-09-30 · accession 0001477932-21-009538 (CashAndCashEquivalentsAtCarryingValue)
  13. 10-K · period ending 2022-09-30 · accession 0001477932-23-000296 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)